// App-Quantinova.ai

P3-10-06 : Combination of BET and FGFR inhibition as a rational therapeutic strategy for invasive lobular breast cancer

Researchers

Presenter

  • Darran P O'Connor

Principal Investigators

  • Kathryn Haley

  • Bruce Moran

  • Brian Mooney

  • Stephen Madden

  • Sudipto Das

  • Oscar Rueda

  • Catriona Dowling

  • Damir Vareslija

  • Suet-Feung Chin

  • Sabine Linn

  • Leonie Young

  • Karin Jirstrom

  • John P Crown

  • Rene Bernards

  • Carlos Caldas

  • William M Gallagher

  • Triona Ni Chonghaile

Medical Centers

  • Royal College of Surgeons in Ireland, Dublin, Ireland

  • University College Dublin, Dublin 4, Ireland

  • University of Cambridge, Cambridge, United Kingdom

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Lund University, Malmo, Sweden

  • St Vincent's University Hospital, Dublin, Ireland

Locations

  • Ireland

  • United Kingdom

  • Netherlands

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • C-C Motif Chemokine Ligand 27

  • Fibroblast growth factor receptor

  • Fibroblast growth factor receptor 1

Drug/Treatment

  • Fulvestrant

  • Navitoclax

  • Tamoxifen

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved